The Russian Direct Investment Fund (RDIF) and the Torlak Institute of Virology, Vaccines and Serums announced the launch Russian Sputnik V vaccine production in Serbia, the RDIF reports.
Serbia became the first state in Southern Europe to produce Sputnik V. It is possible to export the drug to other countries of the region in future. Anti-COVID19 vaccination with a Russian drug started in Serbia on January 6, 2021.
“In accordance with the agreements reached between the RDIF and the Torlak Institute, the production of the Sputnik V vaccine was successfully launched in Serbia in a short time. Serbia was the first European state started production of a Russian vaccine. Since the beginning of this year, the drug has been actively used to vaccinate the people, and due to the establishment of local production, the scale of vaccination will be able to significantly increased, “said Kirill Dmitriev, CEO of the RDIF.
To date, the Sputnik V vaccine has been registered in 60 countries with a total population of 3 billion people. The effectiveness of Sputnik V is 91.6%, as confirmed by the publication of data, in The Lancet, one of the oldest and most respected medical journals in the world. The vaccine is built on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for two vaccinations during vaccination, providing longer immunity than vaccines using the same delivery mechanism for both vaccinations.
